Financial press releases
Medesis pharma recognized as a 2023 prix Galien USA nominee for Best Startup – August 2, 2023
Medesis pharma presents a scientific poster at the international conference of the alzheimer association in Amsterdam – July 13, 2023
Notice of allowance in the United States of the patent protecting the radiation protection treatment against irradiation during a nuclear accident – July 4, 2023
Outcome of the montpellier commercial court ruling in the legal dispute between medesis pharma and bpi france – June 8, 2023
Favorable report from IDSMB experts on the ongoing phase 2 clinical study on Nanolithium in the treatment of Alzheimer’s disease – May 23, 2023
2022 full-year business and earnings – April 17, 2023
Medesis Pharma signs a partnership with Partner International, world leader in transactions between biotechs and pharmaceutical laboratories – April 4, 2023
Medesis pharma sets up bond financing for a potential maximum nominal amount of 2,500,000 euros – March 31, 2023
Medesis Pharma presents a scientific poster at the european RNA leaders congress in Basel – March 13, 2023
New patent filed protecting the technical optimization of the Aonys microemulsion and its efficacy applied for all water-soluble pharmaceutical active ingredients – March 7, 2023
Patent registered in Eurasia to protect the Cesium decorporation drug candidate – Dec. 12, 2022
Medesis Pharma presents a scientific poster at the clinical trials on alzheimer’s disease conference in San Francisco – Nov. 28, 2022
Medesis Pharma announces the constitution of a permanent scientific advisory board of experts in neurodenegerative diseases – Nov. 21, 2022
Medesis Pharma further strengthens its governance – Oct. 4, 2022
Medesis receives a grant from AFM-TELETHON to finance the first phases of the development of NanosiRNA-HD RNA interference therapy for Huntington’s disease – July 20, 2022
Treatment of Alzheimer’s disease with Nanolithium first inclusion of patients in the phase II clinical study – June 13, 2022
Development of NanoManganese for the optimization of radiotherapy in cancer treatment – April 20, 2022
2021 full-year business and earnings – April 13, 2022
Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy – April 5, 2022
U.S. patent protection registration of the future drug allowing the decorporation of cesium – March 24, 2022
Medesis Pharma confirms its eligibility for the PEA-PME – January 14, 2022 (in french only)
Half-year activities and results – September 16, 2021 (in french only)
Repositioning of the NanoManganese program outside the EU after an ANSM refusal – August 26, 2021 (in french only)
Report of the Combined General Meeting – June 15, 2021 (in french only)
Drug candidate development plan for treatment of Huntington disease receives favorable opinion from the EMA – June 3, 2021 (in french only)
Initiation of analyst coverage by Invest Securities – May 7, 2021 (in french only)
Availability of the 2020 Annual Financial Report – April 28, 2021 (in french only)
Annual results and outlook for 2021 (in french only)
Description of the share buyback program and implementation of a liquidity contract – March 12, 2021 (in french only)
Medesis Pharma raises € 7.35m following the very successful IPO on Euronext Paris – February 10, 2021 (in french only)
Medesis Pharma launches its IPO on Euronext Growth Paris – January 26, 2021 (in french only)